Supernus Pharmaceuticals, Inc. (SUPN) Sets 52-Week High; Strong Momentum for Holders

May 17, 2018 - By Robert Crowder

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.12, from 0.98 in 2017Q3. It is positive, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 93 reduced holdings. 43 funds opened positions while 83 raised stakes. 47.19 million shares or 3.19% less from 48.75 million shares in 2017Q3 were reported.
Fdx invested in 5,544 shares or 0.01% of the stock. Tiaa Cref Lc reported 118,832 shares. Gotham Asset Mgmt Ltd holds 139,597 shares. Alpha Cubed Investments Ltd Liability Co owns 6,350 shares for 0.03% of their portfolio. Cortina Asset Limited Liability Com invested 0.29% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Regions Financial reported 7,059 shares or 0% of all its holdings. Ubs Asset Mgmt Americas Incorporated owns 241,076 shares or 0.01% of their US portfolio. Employees Retirement Of Texas, a Texas-based fund reported 40,000 shares. Moreover, Dupont Mngmt Corporation has 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Public Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Aperio Gp Limited Liability Company holds 12,679 shares. Dimensional Fund Advsrs L P owns 1.40 million shares. Millennium Mngmt reported 0.03% stake. Fifth Third Fincl Bank holds 0% or 15,107 shares in its portfolio. Texas Permanent School Fund holds 0.02% or 34,651 shares.

Since January 2, 2018, it had 0 insider buys, and 10 selling transactions for $15.40 million activity. Bhatt Padmanabh P. sold $3.57M worth of stock. $2.18 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares were sold by PATRICK GREGORY S.

The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) hit a new 52-week high and has $58.76 target or 4.00 % above today’s $56.50 share price. The 5 months bullish chart indicates low risk for the $2.93 billion company. The 1-year high was reported on May, 17 by Barchart.com. If the $58.76 price target is reached, the company will be worth $117.08M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 3.17% or $1.85 during the last trading session, reaching $56.5. About 1.10 million shares traded or 54.05% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since May 17, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on August, 1. They expect $0.45 earnings per share, up 40.63 % or $0.13 from last year’s $0.32 per share. SUPN’s profit will be $23.31 million for 31.39 P/E if the $0.45 EPS becomes a reality. After $0.49 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.16 % negative EPS growth.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

Among 6 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Supernus Pharmaceuticals had 7 analyst reports since November 20, 2017 according to SRatingsIntel. The company was maintained on Wednesday, February 28 by Cantor Fitzgerald. Janney Capital upgraded Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, December 4 to “Buy” rating. The firm earned “Buy” rating on Monday, May 14 by FBR Capital. The firm earned “Hold” rating on Wednesday, February 28 by Piper Jaffray. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Tuesday, January 2 by Stifel Nicolaus. The rating was maintained by FBR Capital on Monday, November 20 with “Buy”.

Another recent and important Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news was published by Seekingalpha.com which published an article titled: “Supernus Pharmaceuticals’ (SUPN) CEO, Jack Khattar on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.93 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 41.15 P/E ratio. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: